Dupixent late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Vision loss due to Glaucoma can be prevented if it is detected and treated early
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Alignment of carbon-fiber can be controlled during the 3D printing process
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
Testing supporting allergy diagnosis now accessible to more people in more communities
Asthma patients are more likely to have an asthma attack during winter
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Subscribe To Our Newsletter & Stay Updated